SLC17A9

Across TCGA pan-cancer cohorts, SLC17A9 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC17A9 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SLC17A9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC17A9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, ESCA, and LIHC are the cancer types where SLC17A9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.194	0.802	<.001	20	view →
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
LIHC	OS	Median	All	0.156	0.690	.001	12	view →
BLCA	DFS	Median	All	0.163	0.625	.018	9	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUSC	OS	Median	II,III,IV	0.222	0.615	.034	6	view →
UCEC	DFS	Median	All	0.967	0.829	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC17A9–COAD (OS)

Open the COAD breakdown →